Showing 5551-5560 of 9771 results for "".
- Live Zoster Vaccine Safe and Effective for Patients on TNF Blockershttps://practicaldermatology.com/news/live-zoster-vaccine-safe-and-effective-for-patients-on-tnf-blockers/2460213/The live zoster virus vaccine is safe for people who are currently receiving tumor necrosis factor inhibitor (TNFi) biologic therapies for various indications, according to
- FDA Accepts NDA for Cassiopea's Clascoterone Cream 1% for Acnehttps://practicaldermatology.com/news/fda-accepts-nda-for-cassiopeas-clascoterone-cream-1-for-acne-1/2460209/The FDA has accepted Cassiopea SpA's New Drug Application (NDA) for clascoterone cream 1% for review. Cassiopea, a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological con
- Pinnacle Dermatology Acquires SkinSpeaks Dermatology Clinics in Twin Citieshttps://practicaldermatology.com/news/pinnacle-dermatology-acquires-skinspeaks-dermatology-clinics-in-twin-cities/2460205/Pinnacle Dermatology has acquired SkinSpeaks in the Twin Cities area including locations in Edina, Woodbury, Burnsville, Blaine and Crystal. “We welcome the patients and staff of SkinSpeaks to the Pinnacle Dermatology network of prac
- ASDSA Honors 2019 Patient Safety Heroeshttps://practicaldermatology.com/news/asdsa-honors-2019-patient-safety-heroes/2460203/The American Society for Dermatologic Surgery Association (ASDSA) honored the recipients of its annual Patient Safety Hero awards at the recent ASDS Annual Meeting in Chicago, Illinois. The ASDSA State Legislative Patient Safety Hero Award is presented to a state legislative member who
- FDA Approves Amzeeq Minocycline Foam from Foamixhttps://practicaldermatology.com/news/fda-approves-amzeeq-minocycline-foam-from-foamix/2460194/The FDA has approved Amzeeq (minocycline) topical foam, 4%, from Foamix Pharmaceuticals for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. Amzeeq, formerly known as FMX101, is the first topical minoc
- Data Show Long-term Benefit for Sun Pharma's Ilumyahttps://practicaldermatology.com/news/data-show-long-term-benefit-for-sun-pharmas-ilumya-1/2460189/Long-term follow-up data from ILUMYA® (tildrakizumab-asmn) Phase 3 reSURFACE 1 and 2 trials showed that the significant response rates seen in the initial 52 and 64 weeks, respectively, were maintained over four years for people with moderate-to-severe plaque psoriasis. More than half of
- Lilly: New Data for Treatment of Complex Dermatological Conditions at EADV, Maui Derm NP+PAhttps://practicaldermatology.com/news/lilly-new-data-for-treatment-of-complex-dermatological-conditions-at-eadv-maui-derm-nppa/2460188/New data for Eli Lilly and Company’s Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab have been presented at the 28th annual European Academy of Dermatology and Venereology (EADV) Congress in Madrid. The company says the research h
- Obagi Program at ASDS to Focus on Inclusionhttps://practicaldermatology.com/news/obagi-program-at-asds-to-focus-on-inclusion/2460183/Obagi and actor, producer and activist, Priyanka Chopra Jonas, will lead a panel of top dermatologists in a discussion about the importance of diversity and inclusion in medical aesthetics during the annual meeting of the American Society for Dermatologic Surgery (ASDS) in Chicago next week. 
- Altreno: Exclusive Size Available for Dermatologist Dispensinghttps://practicaldermatology.com/news/altreno-exclusive-size-available-for-dermatologist-dispensing/2460182/Altreno (tretinoin) Lotion, 0.05%, is now available exclusively for physician dispensing in a 20-gram size. Launched last year, Altreno Lotion from Ortho Dermatologics is the first and only tretinoin available in a lotion for the treatment of acne that has been shown to be effectiv
- EPI Health Acquires Worldwide Rights to Rhofade from Aclarishttps://practicaldermatology.com/news/epi-health-acquires-worldwide-rights-to-rhofade-from-aclaris/2460180/EPI Health, LLC, has acquired Rhofade (oxymetazoline hydrochloride) cream, 1% and related intellectual property assets from Aclaris Therapeutics, Inc. Rhofade is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. “We are excited ab